99mTc-labeled SWL specific peptide for targeting EphA2 receptor

Nuclear Medicine and Biology

Volumn 41, Issue 6, 2014, Pages 450-456

  Liu, Yu ^a   Lan, Xiaoli ^a   Wu, Tao ^a,b   Lang, Juntao ^a,c   Jin, Xueyan ^a   Sun, Xun ^a   Wen, Qiong ^a   An, Rui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b The Second People's Hospital of Wuhu   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

EphA2 receptor; Molecular imaging; SPECT; SWL peptide; Tumor imaging

Indexed keywords

EPHRIN RECEPTOR A2; HYDRAZINONICOTINIC ACID; HYDRAZINONICOTINIC ACID SWL PEPTIDE TC 99M; NICOTINIC ACID DERIVATIVE; PEPTIDE; SWL PEPTIDE; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG DISTRIBUTION; DRUG UPTAKE; EX VIVO STUDY; GAMMA RADIATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER CANCER CELL LINE; MALE; MELANOMA CELL; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUDE MOUSE; PEPTIDE ANALYSIS; PHAGE DISPLAY; PROTEIN EXPRESSION; RADIATION MEASUREMENT; RECEPTOR AFFINITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; METABOLISM; MOLECULAR GENETICS; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; HUMANS; ISOTOPE LABELING; MALE; MICE; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTOR, EPHA2; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84901271221     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.03.020     Document Type: Article

References (37)

1. Brantley D.M., Cheng N., Thompson E.J., Lin Q., Brekken R.A., Thorpe P.E., et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21:7011-7026.
2. Pasquale E.B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10:165-180.
3. Kinch M.S., Moore M.B., Harpole D.H. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003, 9:613-618.
4. Ishikawa M., Miyahara R., Sonobe M., Horiuchi M., Mennju T., Nakayama E., et al. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 2012, 76:431-438.
5. Walker-Daniels J., Coffman K., Azimi M., Rhim J.S., Bostwick D.G., Snyder P., et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41:275-280.
6. Noblitt L.W., Bangari D.S., Shukla S., Mohammed S., Mittal S.K. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther 2005, 12:46-53.
7. Thaker P.H., Deavers M., Celestino J., Thornton A., Fletcher M.S., Landen C.N., et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004, 10:5145-5150.
8. Landen C.N., Kinch M.S., Sood A.K. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005, 9:1179-1187.
9. Yamaguchi S., Tatsumi T., Takehara T., Sakamori R., Uemura A., Mizushima T., et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 2007, 110:1469-1477.
10. Hafner C., Becker B., Landthaler M., Vogt T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 2006, 19:1369-1377.
11. Ireton R.C., Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005, 5:149-157.
12. Carles-Kinch K., Kilpatrick K.E., Stewart J.C., Kinch M.S. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002, 62:2840-2847.
13. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
14. Dickerson E., Blackburn W., Smith M., Kapa L., Lyon L.A., McDonald J. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 2010, 10.1186/1471-2407-10-10.
15. Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48:508-518.
16. Gabriel M., Hausler F., Bale R., Moncayo R., Decristoforo C., Kovacs P., et al. Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 2005, 32:1440-1451.
17. Shi J., Wang L., Kim Y.-S., Zhai S., Jia B., Wang F., et al. 99mTcO (MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging 2009, 36:1874-1884.
18. Chen X., Hou Y., Tohme M., Park R., Khankaldyyan V., Gonzales-Gomez I., et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med 2004, 45:1776-1783.
19. 18F-labeled RGD dimer peptide with PEG4 linkers. Eur J Nucl Med Mol Imaging 2009, 36:1296-1307.
20. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., et al. microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.
21. Mansi R., Wang X., Forrer F., Waser B., Cescato R., Graham K., et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011, 38:97-107.
22. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006, 47:492-501.
23. Miao Y., Benwell K., Quinn T.P. 99mTc-and 111In-labeled α-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 2007, 48:73-80.
24. Cheng Z., Xiong Z., Subbarayan M., Chen X., Gambhir S.S. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 2007, 18:765-772.
25. Koolpe M., Dail M., Pasquale E.B. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002, 277:46974-46979.
26. Scarberry K.E., Dickerson E.B., McDonald J.F., Zhang Z.J. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J Am Chem Soc 2008, 130:10258-10262.
27. Wang S., Placzek W.J., Stebbins J.L., Mitra S., Noberini R., Koolpe M., et al. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem 2012, 55:2427-2436.
28. Mitra S., Duggineni S., Koolpe M., Zhu X., Huang Z., Pasquale E.B. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry 2010, 49:6687-6695.
29. Decristoforo C., Faintuch-Linkowski B., Rey A., von Guggenberg E., Rupprich M., Hernandez-Gonzales I., et al. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol 2006, 33:945-952.
30. Nasreen N., Mohammed K.A., Antony V.B. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006, 107:2425-2435.
31. Sun X.L., Xu Z.M., Ke Y.Q., Hu C.C., Wang S.Y., Ling G.Q., et al. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells. Cancer Lett 2011, 312:168-177.
32. Biao-xue R., Xi-guang C., Shuan-ying Y., Wei L., Zong-juan M. EphA2-dependent molecular targeting therapy for malignant tumors. Curr Cancer Drug Targets 2011, 11:1082-1097.
33. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
34. Haubner R., Beer A.J., Wang H., Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 2010, 37(Suppl 1):S86-S103.
35. Fani M., Maecke H.R. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2012, 39(Suppl. 1):S11-S30.
36. Cai W., Chen K., He L., Cao Q., Koong A., Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007, 34:850-858.
37. Cai W., Ebrahimnejad A., Chen K., Cao Q., Li Z.B., Tice D.A., et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 2007, 34:2024-2036.